Price T Rowe Associates Inc Oric Pharmaceuticals, Inc. Transaction History

Price T Rowe Associates Inc

$869 Billion
Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,114,885 shares of ORIC stock, worth $9.48 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,114,885

Previous 1,189,227 6.25%

Holding current value

$9.48 Million

Previous $8.41 Million 35.91%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$7.52 - $11.9 $559,051 - $884,669	-74,342 Reduced 6.25%	1,114,885 $11.4 Million
Q2 2024 Aug 14, 2024	SELL	$6.63 - $12.93 $2.5 Million - $4.88 Million	-377,509 Reduced 24.1%	1,189,227 $8.41 Million
Q1 2024 May 15, 2024	BUY	$8.04 - $16.03 $7.36 Million - $14.7 Million	915,175 Added 140.46%	1,566,736 $21.5 Million
Q4 2023 Feb 14, 2024	BUY	$5.41 - $9.43 $3.28 Million - $5.72 Million	606,446 Added 1344.22%	651,561 $6 Million
Q3 2023 Nov 14, 2023	SELL	$6.05 - $9.28 $108,591 - $166,566	-17,949 Reduced 28.46%	45,115 $274,000
Q2 2023 Aug 14, 2023	BUY	$4.95 - $8.4 $18,438 - $31,290	3,725 Added 6.28%	63,064 $490,000
Q3 2022 Nov 14, 2022	BUY	$3.15 - $5.24 $21,735 - $36,156	6,900 Added 13.16%	59,339 $191,000
Q2 2022 Aug 15, 2022	SELL	$2.7 - $7.07 $30,296 - $79,332	-11,221 Reduced 17.63%	52,439 $235,000
Q1 2022 May 16, 2022	BUY	$4.54 - $16.1 $72,145 - $255,845	15,891 Added 33.27%	63,660 $340,000
Q4 2021 Feb 14, 2022	BUY	$12.01 - $20.3 $573,705 - $969,710	47,769 New	47,769 $702,000

Others Institutions Holding ORIC

# of Institutions

124

Shares Held

66.6M

Call Options Held

7.8K

Put Options Held

700

View Full List

About Oric Pharmaceuticals, Inc.

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $336M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

More about ORIC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Oric Pharmaceuticals, Inc. Transaction History